Top

Published in:

01-01-2012 | Laboratory Investigation - Human/Animal Tissue

Platelet-derived growth factor receptor (PDGFR) expression in primary spinal cord gliomas

Authors: Jason A. Ellis, Peter Canoll, Paul C. McCormick II, Neil A. Feldstein, Richard C. Anderson, Peter D. Angevine, Michael G. Kaiser, Paul C. McCormick, Jeffrey N. Bruce, Alfred T. Ogden

Published in: Journal of Neuro-Oncology | Issue 2/2012

Abstract

Abnormal signaling through the platelet-derived growth factor receptor (PDGFR) has been proposed as a possible mechanism of spinal cord glioma initiation and progression. However, the extent of PDGFR expression in human spinal cord gliomas remains unknown. In this study we perform immunohistochemical analysis of PDGFRα expression in a series of 33 primary intramedullary spinal cord gliomas of different types and grades. PDGFRα was seen to be expressed in a significant subset of these tumors across all major glioma types including ependymoma, oligodendroglioma, pilocytic astrocytoma, astrocytoma, and glioblastoma. These results support the hypothesis that growth factor signaling through the PDGFR may be important for the development of at least a subset of human spinal cord gliomas. Further studies investigating the prognostic significance of PDGFR expression as well as the role of PDGF signaling on the development of intramedullary spinal cord gliomas are warranted.

Hitoshi Y, Harris BT, Liu H, Popko B, Israel MA (2008) Spinal glioma: platelet-derived growth factor B-mediated oncogenesis in the spinal cord. Cancer Res 68:8507–8515PubMedCrossRef

Ellis J, Castelli M, Canoll P, Bruce J, Ogden A (2010) Adult white matter glial progenitors as cells of origin for intramedullary spinal cord tumors: evidence from a novel animal model. AANS/CNS Section on Disorders of the Spine and Peripheral Nerves Abstract. http://univ.cns.org/EducationalTools.htm. Accessed 2 Aug 2011

Ellis JA, Castelli M, Bruce JN, Canoll P, Ogden AT (2011) Retroviral delivery of PDGF to spinal cord progenitor cells drives the formation of intramedullary gliomas. Neurosurgery (in press)

Fakhrai N, Neophytou P, Dieckmann K, Nemeth A, Prayer D, Hainfellner J, Marosi C (2004) Recurrent spinal ependymoma showing partial remission under Imatimib. Acta Neurochir (Wien) 146:1255–1258CrossRef

Barton VN, Donson AM, Kleinschmidt-DeMasters BK, Birks DK, Handler MH, Foreman NK (2010) Unique molecular characteristics of pediatric myxopapillary ependymoma. Brain Pathol 20(3):560–570PubMedCrossRef

Martinho O, Longatto-Filho A, Lambros MB, Martins A, Pinheiro C, Silva A, Pardal F, Amorim J, Mackay A, Milanezi F, Tamber N, Fenwick K, Ashworth A, Reis-Filho JS, Lopes JM, Reis RM (2009) Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. Br J Cancer 101:973–982PubMedCrossRef

Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B, Nister M (1992) Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52:3213–3219PubMed

Haberler C, Gelpi E, Marosi C, Rossler K, Birner P, Budka H, Hainfellner JA (2006) Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and Arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy. J Neurooncol 76:105–109PubMedCrossRef

Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110PubMedCrossRef

10.

Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, Holland E (2009) Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 4:e7752PubMedCrossRef

11.

Razis E, Selviaridis P, Labropoulos S, Norris JL, Zhu MJ, Song DD, Kalebic T, Torrens M, Kalogera-Fountzila A, Karkavelas G, Karanastasi S, Fletcher JA, Fountzilas G (2009) Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin Cancer Res 15:6258–6266PubMedCrossRef

12.

Baruchel S, Sharp JR, Bartels U, Hukin J, Odame I, Portwine C, Strother D, Fryer C, Halton J, Egorin MJ, Reis RM, Martinho O, Stempak D, Hawkins C, Gammon J, Bouffet E (2009) A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours. Eur J Cancer 45:2352–2359PubMedCrossRef

13.

Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, Frenay M, Rampling R, Stupp R, Kros JM, Heinrich MC, Gorlia T, Lacombe D, van den Bent MJ (2008) Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 26:4659–4665PubMedCrossRef

14.

Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD (2006) Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99–08. Clin Cancer Res 12:4899–4907PubMedCrossRef

15.

Reardon DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P, Blomquist E, Gordower L, Schultz H, Raizer J, Hau P, Easaw J, Gil M, Tonn J, Gijtenbeek A, Schlegel U, Bergstrom P, Green S, Weir A, Nikolova Z (2009) Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer 101:1995–2004PubMedCrossRef

16.

Neyns B, Sadones J, Chaskis C, Dujardin M, Everaert H, Lv S, Duerinck J, Tynninen O, Nupponen N, Michotte A, De Greve J (2011) Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol 103(3):491–501PubMedCrossRef

17.

Hainsworth JD, Ervin T, Friedman E, Priego V, Murphy PB, Clark BL, Lamar RE (2010) Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 116:3663–3669PubMedCrossRef

18.

Calzolari F, Malatesta P (2010) Recent insights into PDGF-induced gliomagenesis. Brain Pathol 20(3):527–538PubMedCrossRef

19.

Shih AH, Holland EC (2006) Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett 232:139–147PubMedCrossRef

20.

Westermark B, Heldin CH, Nister M (1995) Platelet-derived growth factor in human glioma. Glia 15:257–263PubMedCrossRef

21.

Di Rocco F, Carroll RS, Zhang J, Black PM (1998) Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. Neurosurgery 42:341–346PubMedCrossRef

22.

Assanah M, Lochhead R, Ogden A, Bruce J, Goldman J, Canoll P (2006) Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J Neurosci 26:6781–6790PubMedCrossRef

23.

Ozawa T, Brennan CW, Wang L, Squatrito M, Sasayama T, Nakada M, Huse JT, Pedraza A, Utsuki S, Yasui Y, Tandon A, Fomchenko EI, Oka H, Levine RL, Fujii K, Ladanyi M, Holland EC (2010) PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev 24:2205–2218PubMedCrossRef

24.

Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC (2001) PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15:1913–1925PubMedCrossRef

25.

Uhrbom L, Hesselager G, Nister M, Westermark B (1998) Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res 58:5275–5279PubMed

26.

Servidei T, Riccardi A, Sanguinetti M, Dominici C, Riccardi R (2006) Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation. J Cell Physiol 208:220–228PubMedCrossRef

27.

Oude Weernink PA, Verheul E, Kerkhof E, van Veelen CW, Rijksen G (1996) Inhibitors of protein tyrosine phosphorylation reduce the proliferation of two human glioma cell lines. Neurosurgery 38:108–113 Discussion 113–104PubMedCrossRef

28.

Assanah MC, Bruce JN, Suzuki SO, Chen A, Goldman JE, Canoll P (2009) PDGF stimulates the massive expansion of glial progenitors in the neonatal forebrain. Glia 57:1835–1847PubMedCrossRef

29.

Masui K, Suzuki SO, Torisu R, Goldman JE, Canoll P, Iwaki T (2010) Glial progenitors in the brainstem give rise to malignant gliomas by platelet-derived growth factor stimulation. Glia 58:1050–1065PubMedCrossRef

30.

Shih AH, Dai C, Hu X, Rosenblum MK, Koutcher JA, Holland EC (2004) Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res 64:4783–4789PubMedCrossRef

31.

Canoll P, Goldman JE (2008) The interface between glial progenitors and gliomas. Acta Neuropathol 116:465–477PubMedCrossRef

32.

Shoshan Y, Nishiyama A, Chang A, Mork S, Barnett GH, Cowell JK, Trapp BD, Staugaitis SM (1999) Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc Natl Acad Sci USA 96:10361–10366PubMedCrossRef

33.

Staugaitis SM, Trapp BD (2009) NG2-positive glia in the human central nervous system. Neuron Glia Biol 5:35–44PubMedCrossRef

34.

Balmaceda C (2000) Chemotherapy for intramedullary spinal cord tumors. J Neurooncol 47:293–307PubMedCrossRef

35.

Harrop JS, Ganju A, Groff M, Bilsky M (2009) Primary intramedullary tumors of the spinal cord. Spine (Phila Pa 1976) 34:S69–S77CrossRef

36.

Isaacson SR (2000) Radiation therapy and the management of intramedullary spinal cord tumors. J Neurooncol 47:231–238PubMedCrossRef

37.

Chamberlain MC, Tredway TL (2011) Adult primary intradural spinal cord tumors: a review. Curr Neurol Neurosci Rep 11(3):320–328PubMedCrossRef

Title: Platelet-derived growth factor receptor (PDGFR) expression in primary spinal cord gliomas
Authors: Jason A. Ellis
Peter Canoll
Paul C. McCormick II
Neil A. Feldstein
Richard C. Anderson
Peter D. Angevine
Michael G. Kaiser
Paul C. McCormick
Jeffrey N. Bruce
Alfred T. Ogden
Publication date: 01-01-2012
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2012
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-011-0666-6

At a glance: The STEP trials

Springer Medicine

Platelet-derived growth factor receptor (PDGFR) expression in primary spinal cord gliomas

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Oligodendrogliomas in children

Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life

Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment

Expression profile of frizzled receptors in human medulloblastomas

Novel approaches to treating leptomeningeal metastases

Primary intracranial plasma cell granulomas presenting as malignant neoplasms